Beck Bode LLC Purchases 79 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Beck Bode LLC grew its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,084 shares of the biotechnology company’s stock after buying an additional 79 shares during the period. Beck Bode LLC’s holdings in United Therapeutics were worth $2,575,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. SG Americas Securities LLC raised its stake in shares of United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock valued at $3,288,000 after buying an additional 9,133 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in United Therapeutics by 19.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock worth $5,901,000 after acquiring an additional 4,100 shares during the period. Comerica Bank boosted its stake in shares of United Therapeutics by 5.9% during the 1st quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock valued at $38,113,000 after purchasing an additional 9,244 shares in the last quarter. QRG Capital Management Inc. grew its holdings in shares of United Therapeutics by 12.4% during the 2nd quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after acquiring an additional 1,692 shares during the period. Finally, Campbell & CO Investment Adviser LLC raised its holdings in United Therapeutics by 163.8% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,245 shares of the biotechnology company’s stock worth $1,813,000 after purchasing an additional 5,120 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the transaction, the chief financial officer now owns 3,210 shares of the company’s stock, valued at $1,108,766.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the completion of the sale, the chief financial officer now owns 3,210 shares in the company, valued at approximately $1,108,766.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $312.48, for a total transaction of $1,124,928.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $40,622.40. The disclosure for this sale can be found here. In the last three months, insiders sold 114,522 shares of company stock valued at $37,671,474. Company insiders own 12.50% of the company’s stock.

United Therapeutics Trading Up 0.0 %

Shares of UTHR stock opened at $345.02 on Wednesday. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average is $337.29 and its two-hundred day moving average is $288.79. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $366.08. The company has a market capitalization of $15.30 billion, a P/E ratio of 16.31, a price-to-earnings-growth ratio of 1.23 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The company had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period last year, the business posted $5.24 earnings per share. Equities analysts forecast that United Therapeutics Co. will post 24.86 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on UTHR shares. Bank of America decreased their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a report on Thursday, August 1st. TD Cowen boosted their target price on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a research report on Thursday, August 1st. JPMorgan Chase & Co. upped their price objective on United Therapeutics from $280.00 to $300.00 and gave the company an “overweight” rating in a research report on Tuesday, May 21st. Finally, UBS Group lifted their price objective on United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a report on Monday, July 8th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $350.36.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.